Bringing the fundamentals into focus…
Back to Royalty Pharma plc
How Royalty Pharma plc stacks up
RPRX · against 70 other Healthcare companies of similar size
Valuation
50/ 100
Below the middle of the pack.
Ranked #48 of 71 · scores higher than 30% of peers
Bars: peers in each 10-point band of the valuation score18 peers with a valuation score of 50–59, including RPRX · Click a bar to see the companies
Why valuation scores 50?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- EBITDA yield is close to the peer norm. EBITDA yield: 3.3% vs peer median 4.0%
- Earnings yield is close to the peer norm. Earnings yield: 2.2% vs peer median 1.5%
- more free cash flow for the price paid: stronger than 90% of peers. Free cash flow yield: 7.8% vs peer median 0.0%
Metric by metric
Position: dot = RPRX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RPRX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 67 reported | 2.8% | 3.0% | 44% | 30% | |
| EBITDA yieldHigher is better · 72 reported | 3.7% | 5.7% | 28% | 50% | |
| Free cash flow yieldHigher is better · 49 reported | 7.8% | 3.8% | 92% | 20% | |
| Book yieldHigher is better · 67 reported | 23.1% | 20.1% | 58% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around RPRX| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.5B USD | 95 | 60 | |
| 2 | 4.61T JPY (≈$31.3B) | 93 | 76 | |
| 3 | 6.17T JPY (≈$42.0B) | 86 | 70 | |
| 4 | 45.9B USD | 84 | 61 | |
| 5 | 34.3B USD | 83 | 57 | |
| 46 | 34.6B USD | 51 | 58 | |
| 46 | 34.0B USD | 51 | 49 | |
| 48 | 67.60T KRW (≈$48.7B) | 50 | 72 | |
| 48 | 36.0B USD | 50 | 46 | |
| 48 | 38.4B USD | 50 | 50 | |
| 51 | 327.3B CNY (≈$45.8B) | 49 | 75 | |
| 51 | 52.9B USD | 49 | 57 | |
| 51 | 32.3B AUD (≈$21.3B) | 49 | 55 | |
| 54 | 28.6B USD | 48 | 60 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score